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Tumors induce de novo steroid biosynthesis
in T cells to evade immunity
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Tumors subvert immune cell function to evade immune responses, yet the complex
mechanisms driving immune evasion remain poorly understood. Here we show that tumors
induce de novo steroidogenesis in T lymphocytes to evade anti-tumor immunity. Using a
transgenic steroidogenesis-reporter mouse line we identify and characterize de novo ster-
oidogenic immune cells, defining the global gene expression identity of these steroid-
producing immune cells and gene regulatory networks by using single-cell transcriptomics.
Genetic ablation of T cell steroidogenesis restricts primary tumor growth and metastatic
dissemination in mouse models. Steroidogenic T cells dysregulate anti-tumor immunity, and
inhibition of the steroidogenesis pathway is sufficient to restore anti-tumor immunity. This
study demonstrates T cell de novo steroidogenesis as a mechanism of anti-tumor immu-
nosuppression and a potential druggable target.
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Steroidogenesis is a metabolic process by which cholesterol isconverted to steroids1. The biosynthesis of steroids startingfrom cholesterol is often termed de novo steroidogenesis1.
Cytoplasmic cholesterol is transported into the mitochondria,
where the rate-limiting enzyme CYP11A1 (also known as
P450 side chain cleavage enzyme) converts cholesterol to preg-
nenolone. Pregnenolone is the first bioactive steroid of the
pathway, and the precursor of all other steroids (Fig. 1a)1,2. The
steroidogenesis pathway has been extensively studied in adrenal
gland, gonads, and placenta. De novo steroidogenesis by other
tissues, known as extra-glandular steroidogenesis, in brain1,3,
skin4, thymus5, and adipose tissues6 has also been reported.
Steroid production as a result of immune response in the mucosal
tissues, such as in the lung and intestine, has been shown to play a
tolerogenic role to maintain tissue homeostasis7,8. However the
physiological and pathological role of extra-glandular ster-
oidogenesis remains largely unknown2.
In cancer, the immunosuppressive tumor microenviroenmnt
(TME) prevents immune cells from mounting an effective anti-
tumor immune response9. Several mechanisms by which cancer
cells evade the immune system have been described10,11. These
include: (1) immune suppression at the TME mediated by
immunosuppressive cells, (2) induction of apoptosis in cytotoxic
T-lymphocytes (CTLs) by the expression of pro-apoptotic ligands
e.g., Fas ligand and TRAIL, (3) dysregulating antigen presentation,
(4) release of immunosuppressive factors such as IL-10 and TGFβ,
and (5) inducing tolerance and immune deviation by mechanisms
including, among others, shifting the balance of Th1 immune
responses (type-1 immune response) to Th2 (type-2 immune
response), and expression of immune inhibitory molecules such as
PD-1 (programmed death-1) and CTLA-4 (CTL antigen-4).
Established tumor often show type 2 immune responses that drive
an immunocompromised and pro-tumorigenic program12–25.
Further understanding of the anti-tumor immunosuppression
would allow us to develop immunotherapies.
Steroid hormones are known immunosuppressive
biomolecules26,27. We recently reported that type 2 CD4+ T cells
(Th2 lymphocytes) induce de novo steroidogenesis to restore
immune homeostasis by limiting the immune response against a
worm parasite28. Thus we sought to determine whether type 2
T cell-mediated steroidogenesis contributes to the generation of a
suppressive niche in the TME.
To study de novo steroidogenesis we generated two transgenic
mouse lines: a fluorescent reporter mouse line (Cyp11a1-
mCherry) and a conditional Cyp11a1 (floxed) knockout mouse
line. We show the presence of de novo steroidogenesis by tumor-
infiltrating T lymphocytes, but not in unchallenged animals or
draining lymph nodes. Genetic ablation of Cyp11a1 in T cells
restricts experimental primary tumor growth and lung metastasis.
Mechanistically, we find that intratumoral T cell steroidogenesis
dysregulates anti-tumor immunity that could be restored by
inhibiting the steroidogenesis pathway pharmacologically. This
study therefore demonstrates that T cell de novo setroidogenesis
is a cause of anti-tumor immunosuppression and a potential drug
target for cancer immunotherapy.
Results
Generation of Cyp11a1 reporter and conditional knockout
mice. Cyp11a1 is the first and rate-limiting enzyme during steroid
production. The expression of Cyp11a1 is therefore also a faithful
biomarker of de novo steroidogenesis1. Therefore, we generated a
reporter mouse line to identify Cyp11a1-expressing steroidogenic
cells definitively (Fig. 1b, c, Supplementary Fig. 1a–d). As
expected, mCherry expression was detected in single-cell sus-
pensions of testis and adrenal glands but negligible to no
expression in the spleen (Fig. 1c) or other tissues including lung,
kidney, blood, liver, bone marrow, lymph nodes, and thymus
(Supplementary Fig. 1b). However, Cyp11a1-mCherry signal was
detected specifically in activated type-2 CD4+ T helper cells (Th2
cells) upon activation in vitro (Supplementary Fig. 1c), as
reported previously28. Cyp11a1 expression was detectable only in
mCherry-expressing T helper cells (Supplementary Fig. 1d).
To determine the functional consequences of cell-type-specific
steroidogenesis we created a Cyp11a1 floxed (Cyp11a1fl/fl) mouse
following EUCOMM/WSI conditional gene targeting strategy29.
Briefly, a knockout-first (tm1a) mouse line was created using a
promoter-driven targeting cassette (Fig. 1d). The tm1amouse was
then crossed with Flp-deleter mice (FlpO) to remove the LacZ
and Neo cassette, and generate a tm1c allele (i.e. Cyp11a1fl/fl).
When crossed with a Cre-driver, the Crerecombinase removes
exon 3 of Cyp11a1 gene and creates a frameshift mutation
(Fig. 1d). Because we had initially detected Cyp11a1 expression
in Th2 cells28, we crossed the Cyp11a1fl/fl line with a Cd4-driven
Crerecombinase to delete Cyp11a1 and prevent de novo
steroidogenesis in all T cells (Fig. 1e). Deletion efficiency of
Crerecombinase in the Cyp11a1 cKO (Cd4-Cre;Cyp11a1fl/fl) mice
was nearly complete in Th2 cells (Fig. 1f). Cyp11a1 cKO mice
showed normal thymic development of T cells, and a normal
distribution in the peripheral tissues (Fig. 1g–i).
In vitro analysis of Cyp11a1 expression in T cells. Exploiting
our Cyp11a1-mCherry reporter line, we assayed a panel of
cytokines commonly found in inflammatory settings, including
tumors, for their ability to induce steroidogenesis in CD4+
T cells. IL4, IL6, IL13, and TSLP induced a strong Cyp11a1-
mCherry signal in in vitro activated CD4+ T cells (Fig. 2a, Sup-
plementary Fig. 2a, b). In contrast, IL12 had an inhibitory effect
on Cyp11a1-mCherry expression (Fig. 2b, Supplementary
Fig. 2c). This indicated that not only Th2 lymphocytes, but also
other T cell types, are capable of de novo steroidogenesis, at least
in vitro. To test this, we differentiated naïve CD4+ or CD8+
T cells into Th1, Th2, Th9, Th17, Tfh, Treg, Tc1, and Tc2 subsets
in vitro. All subsets examined, with the exception of Th1 and
Tc1 cells, exhibited Cyp11a1-mCherry expression when activated,
consistent with an inhibitory role for IL12 in Cyp11a1 regulation
(Fig. 2c, Supplementary Fig. 2d). These data suggest that Cyp11a1
expression, and thereby steroidogenesis, is a default process
during T cell activation, and is inhibited by the presence of IL12.
Overall, of all T cell subtypes generated in vitro, Th2 cells
exhibited the highest percentage of Cyp11a1 expression and
Th1 cells do not express Cyp11a1.
To determine the requirement of Cyp11a1 activity for T helper
cell proliferation and differentiation, we purified naïve splenic
T cells from Cyp11a1 cKO and control mice. We activated the
cells in vitro to generate different subclasses of T helper cells, and
analyzed signature cytokine expression by flow cytometry. In the
absence of Cyp11a1, T cells proliferate normally (Fig. 2d).
Cyp11a1 expression was not required for the differentiation of
any T helper cell type tested as determined by signature cytokine
expression (Fig. 2e, f, Supplementary Fig. 2e). We observed that
deletion of Cyp11a1 in T cells does not interfere with the
plasticity of T helper cells (Fig. 2g, Supplementary Fig. 2f, g).
As a next step, Cyp11a1 induction in T cells was investigated
in vivo.
Tumors induce functional Cyp11a1 expression in T cells.
Tumor-infiltrating T cells are key fate determinants within a
tumor, but are often suppressed30. The steroidogenesis-inducing
type-2 cytokines such as IL4 are also often present in the
TME31,32, thus we next sought to examine the steroidogenic
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capacity (i.e. Cyp11a1 induction) of T cells infiltrating tumors,
and their impact on tumor development. To explore Cyp11a1
expression in vivo, we utilized the well-established B16-F10
melanoma model33–35 and implanted tumors subcutaneously in
Cyp11a1-mCherry reporter mice.
Cyp11a1 expression was detected in immune cells of
established primary tumors, but not in tumor-draining brachial
lymph nodes (LN) or blood (Fig. 3a), indicating that stimulation
occurs in situ. In support of this, stimulation of splenic T cells did
not induce Cyp11a1 expression ex vivo (Fig. 3b, Supplementary
Fig. 3a). The dominant Cyp11a1+ tumor-infiltrating immune
cells were identified as T cells, predominantly CD4+ (helper
T cells, Fig. 3a).
Having identified presence of Cyp11a1-expressing T cells in
established tumors, we next examined expression dynamics
during tumor progression. Using the Cyp11a1-mCherry reporter
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Fig. 1 Generation of a de novo steroidogenesis reporter and conditional knockout mice. a. Schematic of de novo steroidogenesis pathway. Cyp11a1 is the
first and a key rate-limiting enzyme of the pathway. b. Cyp11a1-reporter mice synthesize a fusion protein that self-cleaves due to presence of a T2A peptide
and dissociates into Cyp11a1 and H2B-mCherry. c Cyp11a1-mCherry reporter mice report Cyp11a1 expression accurately. Single-cell suspensions of tissues
and naïve splenic CD4+ T cells were analyzed by flow cytometry. Gating: All cells>Singlets>Live cells>Cyp11a1-mCherry. Representative of three
independent experiments; each experiment contains 3–4 mice. d, e Generation of a Cyp11a1 conditional knockout (cKO) mice. Schematic presentation of
the The targeting allele (d) and T cell-specific Cyp11a1 cKO (Cd4−Cre;Cyp11a1fl/fl) generation (e). f Cyp11a1 knockout efficiency of Cre recombinase in
T cells. Splenic naïve T helper cells from cKO (Cd4-Cre;Cyp11a1fl/fl) mice or control mice (wild type and Cd4-Cre) were activated under Th2 differentiation
condition, and analyzed for Cyp11a1 protein expression by western blot. TATA-binding protein (TBP) used as loading control. g Normal thymic development
of T cells in Cyp11a1 cKO. Thymus was harvested from Cyp11a1 cKO and control (Cd4-Cre and Cyp11a1fl/fl) mice, dissociated into single-cell suspension,
stained with fluorescent conjugated anti-CD4, CD8, B220, CD45, CD25, and CD44 antibodies, and analyzed by flow cytometry. Gating: all
cells>Singlets>Live cells>CD45+B220−>CD4, CD8 (left panel). CD4+CD8+ cells represent double positive (DP) stage, CD4+CD8− and CD4−CD8+ cells
represent single positive (SP) stage, CD4−CD8− cells represent double negative (DN) stage. DN cells of the left panel were gated to show CD25 and
CD44 expression to identify DN1 (CD25−CD44+), DN2 (CD25+CD44+), DN3 (CD25+CD44−), and DN4 (CD25−CD44−). Error bars represent mean
with s.d., N= 4 biologically independent animals. (h, i). Flow cytometric analysis shows normal distribution of Cyp11a1 cKO T cells (CD4+ and CD8+) in
the peripheral blood and spleen. Error bars represent mean with s.d., N= 4 biologically independent animals.
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mice we observed expression of Cyp11a1 in CD4+ T cells which
remained stable during development of the tumor through days 7
and 12. By contrast, CD8+ T cells only expressed Cyp11a1 by day
12 (Fig. 3c, d). Expression dynamics of minor and rare Cyp11a1+
non-T cells (mast cells and basophils) is shown in Supplementary
Fig. 3b, c.
To determine whether Cyp11a1 induction in T cells is
conserved in other tumor types we analyzed an EO771 orthotopic
model of breast cancer36–38 (Fig. 3e–g, Supplementary Fig. 3d).
Again, we found that Cyp11a1 was upregulated in tumor-
infiltrating T cells (Fig. 3e–g), but not in tumor-draining lymph
node or spleen. We also detected minor and rare populations of
other Cyp11a1+ type-2 immune cells, such as mast cells and
basophils (Supplementary Fig. 3d).
Next, we sought to measure the functional output of Cyp11a1
expression. Significant concentrations of the steroid pregnenolone
were detected exclusively in immune cells isolated from tumors,
with negligible levels detected in cells from the spleen (Fig. 3h).
Using the B16-F10 model of experimental metastatic dissemina-
tion39, we determined that lungs with metastatic nodules, but not
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control lungs without metastatic nodules, had elevated levels of
pregnenolone (Fig. 3i).
The presence of tumor cells did not induce or augment the
Cyp11a1 expression in T cells in vitro (Supplementary Fig. 3e).
This indicates that type-2 (Th2) cytokines within the TME induce
Cyp11a1 expression by T cells and this cannot readily be
mimicked in vitro.
Having observed steroidogenic T cells in murine melanoma, we
turned to publicly available transcriptomic data sets to verify our
findings and ascertain relevance in the human setting. We
identified CYP11A1 mRNA expression, and thus steroidogenic
potential, in a range of cancer types including liver, breast,
prostate, lung, kidney, sarcoma, glioma, uterine, cervical,
lymphoma, and melanoma (Supplementary Fig. 3f, g)32. Human
melanoma tissues represented a prominent steroidogenic tumor
type, expressing CYP11A1, HSD3B1, HSD3B2, CYP17A1,
CYP21A1, and CYP11B1 and not expressing CYP11B2 (Fig. 3j,
k). CYP11B2 catalyzes the aldosterone synthesis from corticos-
teroid precursor (Fig. 3k). Together this was indicative of
melanoma-driven production of glucocorticoids (Fig. 3k, Supple-
mentary Fig. 3h).
Interestingly, in melanoma, steroidogenic gene expression was
correlated with IL4 expression (Fig. 3k, Supplementary Fig. 3j), a
key inducer of T cell steroidogenesis28. Moreover, analysis of
human tumor-infiltrating CD4+ T cell transcriptomes, confirmed
CYP11A1 expression (Fig. 3l) implying that CD4+ T cells are a
source of steroids in tumors, mirroring the murine setting.
Collectively these data indicate that in both human and mice,
TILs produce steroids within the tumor.
Gene expression identity of Cyp11a1+ immunocytes in mela-
noma. To reveal the gene expression identity of intratumoral
steroidogenic immune cells and patterns of gene expression at
single-cell resolution, we inoculated B16-F10 subcutaneous tumor
in Cyp11a1-mCherry reporter mice, enriched and purified
intratumoral Cyp11a1-mCherry+ and Cyp11a1-mCherry−
cells by cell sorting into 96-well plates [with a ratio of 79:15
(mCherry+: mCherry−) cells per plate] and performed single-cell
RNA sequencing (scRNA-seq) using the SMART-Seq2 plat-
form40. The majority of cells, ~3000, passed quality control.
Unsupervised hierarchical clustering and visualization with
reduced dimensionality using UMAP (uniform manifold
approximation and projection)41 identified 12 clusters of cells
(Supplementary Fig. 4a). There was no batch effect between
samples (Supplementary Fig. 4b) or impact of sex (Supplementary
Fig. 4c) on clustering, and Cyp11a1-mCherry protein expression
accurately reported Cyp11a1 mRNA expression (Supplementary
Fig. 4d, e). We annotated the clusters based on classical lineage
markers (Supplementary Fig. 4a, f) and their signature gene
expression (Supplementary Fig. 4g). The majority of the
Cyp11a1-expressing cells are T cells as suggested by Cd3e
expression (Supplementary Fig. 4f). T cells constitute the clusters
0, 1, 2, 3, and 8 with cluster-1 displaying genes of CD8+ Tc2 cells;
Cd8a, Cd3e, Gata3, and type 2 cytokines Il4, Il5, and Il13.
Clusters 0, 2, and 3 were CD4+ T helper cells (Cd4+ Cd3e+) as
they expressed Gata3, Il4, and Il13 (Supplementary Fig. 4f). As
T cells were the dominant Cyp11a1-expressing population, we
reanalyzed the data taking only the T cells and displayed in
Fig. 4a–e. The three clusters of Th2 cells represent three closely
related subpopulations (Fig. 4a, b, Supplementary Fig. 4a). The
comparative gene expression between these clusters is shown in
Supplementary Fig. 4i. In Supplementary Fig. 4a, Cluster-4
represents myeloid derived cells, macrophages, and dendritic
cells, but mostly they constitute Cyp11a1-mCherry− cells, though
a very small number of Cyp11a1-mCherry+ cells have been found
in this cluster. Cluster-5 contains B16-F10 cells and melanocytes
from the host mice, and they were Cyp11a1−. Cluster-6 and 9
constitute two different states of the Cyp11a1+mast cells, because
they express Kit (the gene that encodes cKit) and Fcer1 and other
mast-cell-specific proteases such as Mcpt4 and Cma1. The
detailed differences between these two clusters have been shown
in Supplementary Fig. 4j. Cyp11a1+ basophils and eosinophils
(cluster-7) fall in the same cluster. Cluster-8 is a mixed popula-
tion of CD4+ and CD8+ T cells. The number of cells in these two
clusters are not sufficient to make a conclusion of their identity.
Clusters 4, 5, 8, 11, and 10 are constituted by both Cyp11a1-
mCherry+ and Cyp11a1-mCherry− cells. Cyp11a1-mCherry−
cells representing the cells that are most frequently available cells
within B16-F10 tumor, namely B16-F10 cells and macrophages.
Taking Cyp11a1-correlated genes we ran pySCENIC to identify
potential transcription factors regulating Cyp11a1 expression and
found that the GATA family of transcription factors (Gata1, 2, 3)
were predicted to be the controller of the Cyp11a1 locus in these
steroidogenic immune cells (Supplementary Fig. 4h). Gata3 is the
lineage-defining TF of Th2 cells. To validate the prediction that
Gata3 controls Cyp11a1 expression in T helper cells, first we
performed ATAC-seq to identify the open chromatin and
potential locus control region (Fig. 4f). Next, we analyzed Gata3
ChIP-Seq data to confirm that Gata3 is indeed a potential
regulator of the Cyp11a1 locus in Th2 cells (Fig. 4f). The putative
locus control region (blue highlighted region in Fig. 4f) was found
in a closed-chromatin state in naïve and Th1 cells but was open in
Fig. 2 Analysis of Cyp11a1-expressing T cells using Cyp11a1 reporter and cKO mice. a Splenic naïve CD4+ T cells from Cyp11a1-mCherry reporter mice
were purified by negative selection; activated in the anti-CD3e/anti-CD28 antibody coated plates in the presence of cytokines for 3 days, rested for 2 days,
restimulated 6 h, and Cyp11a1-mCherry expression was analyzed by flow cytometry. N= 3 (except IL33 where N= 2). b IL12 inhibits Cyp11a1 expression.
Splenic naïve CD4+ T cells from Cyp11a1-mCherry reporter mice were activated as mentioned above (a) for 5 days and Cyp11a1-mCherry expression was
analyzed by flow cytometry. N= 6. c Splenic naïve CD4+ and CD8+ T cells from Cyp11a1-mCherry reporter mice were activated in vitro under Th1, Th2,
Th9, Th17, Tfh, Treg, Tc1, and Tc2 differentiation conditions (activation 3 days, resting 2 days), and Cyp11a1-mCherry expression was analyzed by flow
cytometry. N= 6 (Tc1, Tc2), N= 4 (Th1, Th9, Tfh), and N= 5 (Treg, Th17). d Splenic naïve CD4+ T cells were purified from Cyp11a1 cKO, Cd4-Cre, and
Cyp11a1fl/fl mice, stained with CellTrace Violet, activated in vitro, and cell proliferation was determined by a flow cytometric dye decay assay.
Representative cell proliferation profiles are shown in the left panel and a comparison of the cell division index is shown in right panel. N= 9. e Splenic
naïve CD4+ T cells were activated in vitro in the absence of any exogenous cytokine or cytokine-neutralizing antibody, and cytokine expression was
determined by flow cytometry. N= 6. f Splenic naïve CD4+ T cells were activated in vitro under Th17 or Th2 differentiation conditions, and cell type-
specific signature cytokine expression was determined by flow cytometry. N= 3 (Th17), N= 6 (Th2). g Splenic naïve CD4+ T cells were activated in vitro
under Th1 or Th2 differentiation condition. After 3 days Th1 cells were allowed to differentiate under Th2-polarizing conditions (Th1 > Th2), and Th2 cells
were allowed to differentiate under Th1-polarizing conditions (Th2 > Th1). Th1 or Th2-specific cytokine expression was determined by flow cytometry. N=
6. All error bars in this figure represent mean with s.d. P-value was calculated using unpaired two-tailed t-test. Representative of three independent
experiments. N represents biologically independent animals.
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Th2 and Th17 cells and was occupied by Gata3 in Th2 cells
(Fig. 4f).
All the Cyp11a1-expressing T cells express steroidogenic type-2
cytokines Il4 and Il13 (Fig. 4e, Supplementary Fig. 4f). T cells
express the cognate receptor for IL4 (Il4ra) indicating that these
cells are receptive to the steroidogenic signal (Supplementary
Fig. 4f).
The prediction of glucocorticoids in the tumor prompted us to
check the cognate receptors in the tumor-infiltrating immune
cells. We found that the glucocorticoid receptor Nr3c1 was
expressed in all tumor-infiltrating immune cells (Supplementary
Fig. 4k).
Ablation of T cell steroidogenesis restricts tumor growth. To
determine the functional consequences of T cell-driven ster-
oidogenesis in tumors we subcutaneously implanted Cyp11a1
cKO mice with B16-F10 cells. Genetic deletion of Cyp11a1 in
a
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T cells significantly restricted primary tumor growth rates and
final volumes (Fig. 5a). Similarly, in the experimental metastasis
model, impaired lung colonization was observed in the absence
of T cell-expressed Cyp11a1. There was a significant reduction
in number of metastatic foci in lungs of Cyp11a1 cKO mice
compared to the control mice (Fig. 5b). In the B16-F10 sub-
cutaneous melanoma model, topical application of exogenous
pregnenolone at the primary tumor site was sufficient to
compensate for the Cyp11a1 deficiency, restoring tumor growth
to levels comparable with control mice (Fig. 5c). This suggests
that the tumor restriction was a consequence of the absence of
pregnenolone synthesis. Similar results were obtained using the
EO771 breast cancer orthotopic tumor model: deletion of
Cyp11a1 in T cells restricted dissemination to and nodule
Fig. 3 Tumors induce Cyp11a1 expression in T cells in vivo. a B16-F10 cells were injected subcutaneously into the Cyp11a1-reporter mice. After 12 days
brachial lymph node (LN), blood, and tumor tissues were analyzed by flow cytometry. Gating strategy: Singlets>Live cells>CD45,Cyp11a1-mCherry. N= 5.
CD45+Cyp11a1-mCherry+ cells were further gated to show T helper cell (CD4+CD3e+) expression of Cyp11a1. b Splenic cells were purified from tumor-
bearing Cyp11a1-reporter mice, and restimulated in vitro using PMA/ionomycin and analyzed by flow cytometry. N= 9. c, d B16-F10 cells were injected
subcutaneously into the Cyp11a1-mCherry reporter mice. After 5, 7, and 12 days tumor tissues were analyzed by flow cytometry to detect the CD4+ T cells
(c), CD8+ T cells (d) N= 4. All cell>Singlets>Live cell>CD45+>CD4+CD3e+ or CD8+CD3e+. e–g EO771 cells were injected into the mammary fat pad of
Cyp11a1-reporter mice. After 15 days, tumor tissues and tumor-draining LN were analyzed by flow cytometry to detect the Cyp11a1-mCherry expression in
CD4+ T cells (e, f) CD8+ T cells (g). Gating: All cell>Singlets>Live cell>CD45+>CD4+TCRb+ or CD8+TCRb+. e Representative FACS profile of Cyp11a1+
CD4+ T cells. f, g Representative graphical presentation of one experiment showing Cyp11a1-expressing CD4 and CD8 T cells. N= 4. h B16-F10 tumor-
infiltrating leukocytes (TIL) and splenocytes were purified from tumor-bearing mice on post-inoculation day-12, cultured for 48 h, and the supernatant
was analyzed by ELISA to measure pregnenolone. N= 12, pooled analysis of three independent experiments. i Metastasized lungs were harvested 10 days
post-B16-F10 intravenous injection in C57BL/6 mice, dissociated into single-cell suspension, cultured for 48 h, and the supernatant was analyzed by ELISA.
Naïve uninfected lungs (normal lung) were used as control. N= 6, pooled analysis of two independent experiments. j Hierarchical clustering of
steroidogenic genes and IL4 mRNA expression across 44 melanoma patient samples (GEO: GSE19234). k Schematics showing glucocorticoid synthesis
pathway. l Frequency distribution histogram showing CYP11A1 mRNA expression (normalized read counts, log10 scale) across 22 melanoma patients’
tumor-infiltrating CD4+ T cells (EGAD00001000325). Individual data points for CYP11A1 expression are shown in Supplementary Fig. 3i. All error bars in
this figure represent mean with s.d. P-values were calculated by unpaired two-tailed t-test. N represents biologically independent animals.
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Fig. 4 Revealing gene expression identity of intratumoral Cyp11a1+ T cells by scRNAseq. a, b UMAP visualization of the tumor-infiltrating T cells (a)
with annotations of the clusters (b). Tc1 represents type-1 CD8+ T cells, Tc2 represents type-2 CD8+ T cells, and Th2 represents type-2 CD4+ T cells.
c, d mCherry protein expression accurately reports Cyp11a1 mRNA expression. Cyp11a1-mCherry protein expression according to the flow cytometry
(FACS) data (c). Cyp11a1 mRNA expression in the scRNA-seq data (d). e Expression of cell-type-specific signature genes that were used to annotate the
clusters. f Determination of Cyp11a1 locus control region. Open chromatin regions were identified by ATAC-seq of T helper cells. In vitro generated Th2 and
Th17 cells were used as positive control. Naïve and Th1 cells were used as negative control. Gata3 ChIP-seq data were analyzed to determine the binding
site. The open chromatin region where Gata3 occupy is highlighted blue and considered as locus control region.
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formation in the lung (Fig. 5d). Importantly, in both tumor
models, pharmacological inhibition of Cyp11a1 by aminoglu-
tethimide (AG) was sufficient to recapitulate the tumor
restriction phenotype resulting from Cyp11a1 genetic ablation
(Fig. 5e, f). Together, these data indicate that T-cell-derived
steroids can support tumor growth and both genetic and
pharmacological interference with the pathway can restrict
tumor growth.
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Fig. 5 Ablation of T cell steroidogenesis restricts experimental tumor growth and metastasis. a Left-panel: B16-F10 subcutaneous tumor growth curve
assessed in T cell-specific Cyp11a1 cKO (cKO) and Cd4-Cre control mice. N= 5. Representative of four independent experiments. Right panel: graphical
presentation of end-point tumor volume. N= 20 (ctrl), 23 (cKO). Pooled data of four independent experiments. Each point represents an individual animal.
Error bars represent mean ± s.e.m., unpaired two-tailed t-test. b Left panel: Representative photograph of pulmonary metastatic foci produced 10 days after
tail vein injection of B16-F10 cells in cKO and control (Cre and WT) mice. N= 5. Right panel: graphical presentation of the numbers of lung metastatic foci.
N= 14 (ctrl), 16 (cKO), pooled data of three independent experiments, each point represents an individual animal, error bars represent mean with s.d.
Unpaired two-tailed t-test. c cKO and Cd4-Cre control mice were injected with B16-F10 cells. Pregnenolone or vehicle (DMSO) applied topically at the
primary tumor site every 48 h. Tumor volume was measured at the end-point at day 12. N= 5. Each point represents an individual animal. Error bars
represent mean ± s.e.m. P-value was calculated by one-way ANOVA with Tukey Post hoc test. d Representative hematoxylin and eosin stained histologic
photograph of pulmonary metastatic foci produced 10 days after tail vein injection of EO771 cells in Cyp11a1 cKO and Cyp11a1fl/fl mice. Graphical
presentation of the numbers of lung metastatic foci (right panel). N= 10. Error bars represents mean with s.d. Unpaired two-tailed t-test. Representative of
two independent experiments. e B16-F10 cells were injected subcutaneously in C57BL/6 mice with or without Cyp11a1 inhibitor aminoglutethimide (AG).
AG treatment was continued with a 48-h interval. N= 5. Error bars represent mean ± s.e.m. Two-way ANOVA. Representative of two independent
experiments. f EO771 cells were injected into the mammary fat pad in C57BL/6 mice with or without Cyp11a1 inhibitor AG. AG treatment was continued
with a 48-h interval. N= 5. Error bars represent mean ± s.e.m. One experiment. In this figure, N represents biologically independent animals.
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Inhibition of T cell steroidogenesis boosts tumor immunity.
Steroid hormones can induce an immunosuppressive M2-like
phenotype in macrophages26,42,43 cell death and anergy in
T cells26,44–46, tolerance in dendritic cells26,47–49 and increase the
frequency of Treg cells50–52. Therefore, we tested whether ster-
oidogenic T cells support tumor growth through the induction of
immunosuppressive phenotypes in infiltrating immune cells. To
determine whether intratumoral macrophages were M1 or M2
type, we purified tumor-infiltrating macrophages and analyzed
mRNA expression of the M2-macrophage signature genes Arg1
and Tgfβ1. In tumor-infiltrating macrophages from Cyp11a1 cKO
mice, Arg1 and Tgfβ1mRNA expression was significantly reduced
compared to the control mice, indicating fewer of the tumor-
supporting M2 macrophages in the T cell-specific Cyp11a1
knockout mice (Fig. 6a). We confirmed changes in macrophage
characteristics at the protein level, showing a significant decrease
in Arg1+ macrophages (M2) with coincident increase in tumor-
infiltrating iNOS+ macrophages (M1) upon T cell-specific
Cyp11a1 deletion (Fig. 6b, c). Hence, depletion of Cyp11a1 in
T cells increases the M1/M2 macrophage ratio in the TME.
Consistent with enhanced tumor immunity, we found
significantly higher levels of the inflammatory cytokines Ifnγ
and Tnfα expression in CD8+ T cells following Cyp11a1 ablation
(Fig. 6d). Moreover the expression of the co-inhibitory
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receptors53 PD1 and TIGIT on tumor-infiltrating T cells was
reduced in CD4+ TILs in the Cyp11a1 cKO mice compared with
control littermates (Supplementary Fig. 5a). The data indicate
greater T cell functionality and less exhaustion in the Cyp11a1
cKO mice.
To test cytotoxic capacity of T and NK cell populations, we
examined the degranulation response of these cells by analyzing
cell surface expression of CD107a/LAMP1 in tumor-infiltrating T
and NK cells. We observed a significantly increased proportion of
degranulating CD107a+CD8+ T cells in Cyp11a1 cKO mice
compared to control mice (Fig. 6e). The degranulation response
in NK cells and CD4+ T cells was also enhanced (Fig. 6f, g).
Finally, we observed that the proportion of intratumoral Tregs
was decreased (Fig. 6h). Altogether these data suggest that
inhibition of T cell steroidogenesis by genetic deletion of Cyp11a1
changes immune cell composition in the tumor microenviron-
ment in favor of anti-tumor immunity.
Similar to the genetic deletion of Cyp11a1, application of the
Cyp11a1 inhibitor aminoglutethimide significantly increased
frequencies of M1 macrophages and degranulating T and NK
cells (Fig. 6i–l, Supplementary Fig. 5b), recapitulating anti-tumor
phenotypes. Cyp11a1 inhibition also decreased the number of M2
macrophages in the tumor (Fig. 6i). Together, these data
demonstrate the potential to stimulate anti-tumor immunity
through pharmacological suppression of Cyp11a1-dependent
steroidogenesis pathways.
Discussion
The endocrine importance of systemic steroid hormones is well
documented in regulating cell metabolism and immune cell
function but the intracrine, autocrine, and paracrine role of local
cell-type-specific steroidogenesis is less clear, particularly in
pathologies such as cancer1,2. This is in part due to the lack of
tools to study steroidogenesis in a tissue-specific manner in vivo.
To overcome this, we generated a Cyp11a1-mCherry reporter and
a conditional Cyp11a1 knockout mouse strain to identify de novo
steroidogenic cells and study their role in vivo. Using these dis-
covery tools, complemented by pharmacological intervention, we
uncovered an anti-tumor immune suppression mechanism that
may be exploited clinically to boost the anti-tumor immunity
(Fig. 7).
The TME harbors innate immune cells (such as macrophages,
neutrophils, eosinophils, mast cells, myeloid derived suppressor
cells, dendritic cells, and natural killer cells), adaptive immune
cells (such as T and B cells), stromal cells (such as fibroblasts,
endothelial cells, pericytes, mesenchymal cells), and cancer cells.
The presence of immune cells in the tumor microenvironment
raises a long-standing question: How tumors evade the immune
surveillance and anti-tumor immunity? The present under-
standing suggests that the balance between protective anti-
tumoral immune cells (and other protective factors) and pro-
tumoral immunosuppressive cells (and other immunosuppressive
factors) determines the fate. Anti-tumoral immune cell subsets
includes Th1, Tc1 (CD8+ CTL), M1 macrophage, DC1 which are
antagonized by Th2, M2, tolerogenic DC, immature DC, DC2,
Treg, and myeloid-derived suppressor cells. Established tumors
often foster immunosuppressive and tolerogenic immune cells. In
this report, the discovery of immune cell-mediated steroid bio-
synthesis in the TME explains how an immunosuppressive TME
can be achieved. Previously it has been shown that steroids induce
anergy and cell death in T cells44–46,54, M2 phenotype in
macrophages42,43, tolerance in DCs47–49, and increase the fre-
quency of Treg cells50–52. Here we demonstrate that tumor-
infiltrating T cells can produce steroids and that the inhibition of
T cell-mediated steroid biosynthesis tips the balance toward
protective immunity. We have shown that ablation of intratu-
moral steroids by deleting Cyp11a1 in T cells reduced the number
of M2 macrophages and Tregs, and increased the number of M1
macrophages, functional T cells, and NK cells. The results suggest
that the secreted steroid works in a paracrine manner that effect
on other infiltrating immune cells as expected. All these cell types
are known to be crucial in regulating anti-tumor immunity and
immunosuppression. Therefore, in the absence of intratumoral
steroids, anti-tumor immunity is more effective and restricts
tumor progression. Importantly, this pathway can be targeted
pharmacologically. This may be exploited therapeutically in three
ways: (1) steroidogenic gene expression or the presence of ster-
oids might be used to stratify the patients, (2) use of pharma-
cologic drug (i.e. anti-steroidogenic) can convert the TME into
protective type-1 inflammatory condition by reducing the steroid
level, and (3) immunotherapy should work better in absence of
immunosuppressive steroids.
Single-cell level transcriptomic analysis revealed important
findings pertaining to tumor immune infiltrates and provide a
rich resource for cancer immunologists. We identified three dis-
tinct classes of immune cells with steroidogenic potential, T cells
(Th2 and Tc2, major population), mast cells (minor population),
basophils (minor population), and a few monocyte/macrophages.
GATA factors are revealed as key drivers of Cyp11a1 expression
in immune cells. In Th2 cells Gata3 occupies the Cyp11a1 locus.
Cyp11a1+ Th2 cells outnumbered other types of Cyp11a1-
expressing cells. Hence deletion of Cyp11a1 in T cells was
Fig. 6 Inhibition of T cell steroidogenesis stimulates anti-tumor immunity. a–h Comparing Cyp11a1 cKO and Cd4-Cre control mice with B16-F10 cells
injected subcutaneously. Representative of three independent experiments. a Tumor-infiltrating macrophages (Lin−CD11b+) were purified by cell sorting at
day 12. Arg1 and Tgfβ1 mRNA expression was quantified by RT-qPCR, with mRNA expression level normalized by Gapdh mRNA expression. N= 6.
b, c Tumor-infiltrating macrophages (Lin−CD11b+F4/80+) analyzed by flow cytometry at day 12 to examine iNOS and Arg1 expression. Representative
FACS profile of the expression (b). Representative graphical representation of one experiment (c). N= 5. d Tumor-infiltrating CD3e+CD8+ T cells purified
by cell sorting at day 12, reactivated ex vivo, and Ifnγ and Tnfα mRNA expression quantified by RT-qPCR, with mRNA expression level normalized by Rplp0
expression. N= 6. e Cytotoxic T-lymphocyte degranulation assay. CD107a/LAMP1 expression on tumor-infiltrating CD8+ T cells was analyzed by flow
cytometry after 12 days post-inoculation of B16-F10 cells. N= 8 (ctrl), 9 (cKO) Gating: All cells>singlets>live cells>CD8+ T cell>CD107a. f NK cell
degranulation assay by measuring CD107a/LAMP1 expression on tumor-infiltrating NK cells. N= 8 (ctrl), 9 (cKO). Gating: All cells>singlets>live cells>NK
cells>CD107a. g CD4+ T cell degranulation assay by measuring CD107a/LAMP1 expression on CD4+ T cells. N= 8. Gating: All cells>singlets>live
cells>CD4+ T cell>CD107a. h Flow cytometric analysis to show the changes in B16-F10 subcutaneous tumor-infiltrating Treg (CD4+CD3e+FoxP3+)
populations upon Cyp11a1 deletion. N= 9. i–l Comparing immunophenotype in Cyp11a1 inhibitor, AG, treated and untreated mice with B16-F10 cells injected
subcutaneously. All are representative of two independent experiments. i Representative FACS profile to show iNOS and Arg1 expression in tumor-
infiltrating CD45+Lin−CD11b+F4/80+ macrophages (left panel). Graphical presentation the iNOS and Arg1 expression of a representative experiment
(right panel). N= 5. j–l CD107a/LAMP1 expression on CD4+ T cells (j), CD8+ T cells (k) and NK cells (l) was analyzed by flow cytometry after 12 days
post-inoculation of B16-F10 cells. N= 4 (ctrl), 3 (cKO). Gating: All cells>singlets>live cells>CD4+ or CD8+ T or NK cells>CD107a. In this figure, all error
bars represent mean with s.d. P-value was calculated by unpaired two-tailed t-test. N represents biologically independent animals.
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sufficient to remodel the TME for more effective anti-tumor
immune responses. In the in vitro setting, we observed that Tregs
and other T helper cell types (except Th1) can upregulate
Cyp11a1 expression, but in the in vivo setting we noticed that
only Th2 cells were Cyp11a1+. We did not find Cyp11a1-
expressing Tregs or any other T helper cell types in the B16-F10
TME. The presence of Cyp11a1+ non-T cells indicates that in a
different context, such as in different tumor types, the steroido-
genic population may vary and other hematopoietic cells may
also produce steroids. Future studies are essential to gain detailed
insight of immune cell-mediated intratumoral steroidogenesis in
different tumor type. It would be interesting to know why CD4+
T cells upregulate Cyp11a1 expression specifically in the TME,
and not in the secondary lymphoid organs. This could be a result
of the fact that Th2 cells are numerous in tumors but not in the
spleen and lymph nodes. Therefore, further studies are needed to
delineate whether this is a result of an increased Th2 cell abun-
dance in tumors, and/or an enhanced Cyp11a1 expression per
individual Th2 cell.
The induction of type-2 immune response in tumors such as
breast, pancreatic, melanoma, glioma, cervical, lung, and bladder
cancer has been previously reported, both in humans and mice,
and its roles in the promotion of cancer by immunosuppression
are known12–25. As expected, reanalysis of publicly available
transcriptomic datasets showed evidence of many human tumor
types expressing steroidogenic genes. In melanoma, we show
evidence of steroidogenic gene expression being correlated with
type-2 immune signature genes such as IL4. The limitation of this
analysis is that it does not confirm the cellular source of CYP11A1
expression because the transcriptomes were obtained from bulk
RNAseq of whole tumors. In the future, single-cell RNA
sequencing of tumor-infiltrating Th2 cells from patients may
provide direct evidence and further insights. Analysis of publicly
available single-cell RNA sequencing datasets of human tumor-
infiltrating T cells revealed that all the available datasets are from
tumors that predominantly raised Th1-mediated immune
responses. Therefore, as expected, we observed no or only a few
CYP11A1-expressing cells in these data sets (data not shown).
This is consistent with our hypothesis in the sense that we expect
CYP11A1 expression predominantly in tumors exhibiting type-2
immune responses.
The study adds to the concern raised by recent studies about
proper use of steroids, particularly glucocorticoids, in solid
tumors as a part of the disease management, specifically when we
seek to boost anti-tumor immune response55–62. Glucocorticoids
have been used in clinical oncology for over a half a century, and
at present these are routinely used to alleviate edema in patients
with intracranial lesions and are first-line agents to suppress
immune-related adverse events that arise with the immu-
notherapies. Therefore, further studies are required to evaluate
the use of synthetic steroids if the tumors itself induces gluco-
corticoid synthesis. Reduction of intratumoral steroidogenesis
may open a window for immunotherapies to work better at
lower doses.
Similar experimental approaches can in future provide in depth
mechanistic insights into other extraglandular (local) steroido-
genic cell types such as adipose cells, neuron, osteoblasts, astro-
cytes, microglia, skin, trophoblast, and thymic epithelial cells. Our
Cyp11a1-mCherry reporter mouse line can be used as a discovery
tool to identify undiscovered steroidogenic cell types in tolero-
genic physiological conditions such as pregnancy, mucosal tol-
erance, and inflammatory and immunopathological conditions.
Their functional role can be dissected by using Cyp11a1 cKO
mice using tissue-specific Cre-drivers. Nevertheless, cancer is a
proven context where tumors hijack this pathway for immune
evasion. Further studies in diverse physiological scenarios would
be of great interest to more broadly understand the role of
immune cell de novo steroidogenesis in regulating inflammation
and immunity.
Methods
Mice. The use of all mice in this research article were in accordance with the UK
Animals in Science Regulation Unit’s Code of Practice for the Housing and Care of
Animals Bred, Supplied or Used for Scientific Purposes, the Animals (Scientific
Procedures) Act 1986 Amendment Regulations 2012. All experimental procedures
were performed under UK Home Office Project licenses (PPL 80/2574 or PPL
P8837835 or PPL P6B8058B0), which were reviewed and approved by the Medical
Research Council Laboratory of Molecular Biology (PPL 80/2574 or PPL
P8837835) and Wellcome Sanger Institute (PPLP6B8058B0) Animal Welfare and
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Fig. 7 Graphical abstract of the discovery. T cell-mediated de novo steroidogenesis in the tumor microenvironment promotes tumor growth by inhibiting
anti-tumor immunity, in part by inducing M2 phenotype in macrophages and suppressing T and NK cell function. Genetic deletion of Cyp11a1 or
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Ethical Review Bodies (AWERB). Sample sizes were determined based on previous
experience and a priori power analysis (G* Power). Housing conditions at the
Sanger Institute: all the mice used in this study, were maintained in specific
pathogen-free unit on a 12-h light and 12-h dark cycle (lights off at 7:30 pm and no
twilight period). The ambient temperature was 21 °C with a maximum variation of
±2 °C. The humidity was 55 ± 10%. Mice were housed for phenotyping with a
stocking density of 3–5 mice/cage (dimensions of caging: (L ×W ×H) 365 × 207 ×
140 mm, floor area 530 cm2) in individually ventilated caging (Tecniplast Seal
Safe1284L) receiving 60 air changes/h. In addition to Aspen bedding substrate, we
provide standard environmental enrichment of two nestlets, a cardboard Fun
Tunnel and three wooden chew blocks. Given water and diet were available all the
times. Mice were fed on Mouse Breeders Diet (Lab Diets, 5021-3). Animals
recruited to studies at ARES Medical Research Council animal facility remained
socially housed in individually ventilated cages, at ambient temperature and with
cage enrichment. Animals of each genotype were randomly assigned to experi-
mental groups, and where possible, technicians performing the experiment were
blinded to experimental groups and treatments.
Generation of a Cyp11a1-mCherry reporter mouse line. Using CRISPR_Cas9
technology we introduced double-strand DNA breaks 5′ and 3′ adjacent to the
Cyp11a1 termination codon in exon 9 to facilitate the introduction of our targeting
construct. The 5′ and 3′ arms of homology were designed to remove the Cyp11a1
termination codon and 100 bp of the 3′ UTR immediately downstream and replace
it with a minimal T2a self-cleavage peptide followed by the fluorescent marker
mCherry. Using the web-based tool designed by Hodgkins et al.63, two sgRNAs
were identified 5′ and 3′ adjacent to the Cyp11a1 termination codon. The guide
sequences were ordered from Sigma Genosys as sense and antisense oligonucleo-
tides, and annealed before individually cloning into a human U6 (hU6) expression
plasmid (Addgene # 41824). Next, we generated targeted ES cell (ESCs) through
nucleofection of 3 × 106 JM8 ESCs with 2 μg Cyp11a1 circular targeting construct,
1.5 μg of each hU6_sgRNAs, and 3 μg a plasmid expressing human codon-
optimized CAS9 driven by with the CMV promoter (Addgene # 41815). 48 h post
transfection the media was changed for G418 selection media (165 ug/ul). Con-
firmation of the correct targeting events were confirmed by quantitative PCR
(qPCR) for loss of heterozygosity (LOH) and the presence of the selectable marker,
and long range (LR) PCR and Sanger sequencing. Following blastocyst injection
and chimaera breeding three F1 Cyp11a1 +/mCherry-Neo mice were bred to
pCAGGSs-Flpo64 mice to remove the neomycin selectable marker to generate
Cyp11a1+/mCherry mice.
Genotyping primer sequence (Supplementary Fig. 1a)
GF ATGGTGACACAGACCTCCTTG
GR CCCAGGAACAGAAAGGCTTG
R2R AGGCGCATAACGATACCACG
R1R GGATTCTCCTCCACGTCACCG
Generation of a Cyp11a1 cKO mice. Cyp11a1fl/fl mice were generated by crossing
Cyp11a1tm1a(KOMP)Wtsi mice with a previously reported Flp-deleter (FlpO) line64.
Cyp11a1fl/fl mice were crossed with Cd4-cre mice to generate the Cyp11a1
cKO mice.
Syngeneic mouse tumor models. B16-F10 melanoma model: the C57BL/6
derived B16-F10 melanoma cell line was purchased from American Type Culture
Collection (ATCC) and cultured in Dulbecco’s Modified Eagle medium (DMEM,
Life Technologies), supplemented with 100 U/mL penicillin/streptomycin and
10% fetal bovine serum (FBS; Life Technologies, Invitrogen). For the primary
tumor growth assay, 2.5 × 105 B16-F10 cells were injected subcutaneously into the
shoulders of either wild type (WT) C57BL/6 mice, Cd4-Cre, Cyp11a1fl/fl or Cd4-
Cre;Cyp11a1fl/fl mice. Once tumors were palpable, non-invasive tumor measure-
ments were recorded daily and volumes calculated using the following formula
(π/6) (shortest length × longest length). After 11 or 12 days animals were killed and
tissues collected for analysis. For the experimental metastasis assay, 5 × 105 B16-
F10 cells in a volume of 0.1 ml PBS were injected intravenously into the tail vein.
After 10 days (±1 day) the mice were killed via cervical dislocation, and their lungs
removed and rinsed in phosphate-buffered saline. The number of B16-F10 colonies
on all five lobes of the lung were counted macroscopically. Exogenous pregneno-
lone treatment: On days 5, 7, and 9, tumor-bearing mice received 10 μl of vehicle or
pregnenolone (20 mg/ml) in DMSO via topical application at tumor site. Tumor
volumes were recorded until the experimental endpoint on day 12. Orthotopic
EO771 breast cancer model: the EO771 breast cancer cell line was purchased from
CH3 BioSystems and cultured in RPMI (Sigma) supplemented with 10% FBS, 1%
PS, and 10 mM HEPES. In all, 2.5 × 105 cells were injected into the 4th inguinal
mammary fat pad of Cyp11a1-mCherry reporter mice. Tumors and inguinal lymph
node were collected after 15 days of tumor development.
Lung colonization of EO771 cells: 4 × 105 cells were injected intravenously in to
the tail vein. After 10 days (±1 day) the mice were killed via cervical dislocation,
and their lungs were removed, rinsed in PBS and fixed in 10% neutral buffered
formalin. The fixed lungs were paraffin embedded and sections stained with
Hematoxylin and Eosin using routine histology protocols. The microscopic images
were captured in Olympus with ×10 magnification and the number of metastatic
foci were counted. Treatment with aminoglutethimide (AG): for both the B16-F10
and E0771 models 200 μl of a 2-mg/ml AG or vehicle were administered via the
intraperitoneal route. The first dose was administered concurrently with cell
implantation and repeated every 2 days thereafter.
Tumor tissue processing. Tumors were mechanically dissociated and digested in
1 mg/ml collagenase D (Roche), 1 mg/ml collagenase A (Roche), and 0.4 mg/ml
DNase I (Sigma) in IMDM media containing 10% FBS, at 37 °C for 40 mins. EDTA
was added to all samples to neutralize collagenase activity (final concentration 5
mM) and digested tissues were passed through 70μm filters (Falcon).
Cell sorting. Once processed, single-cell suspension tumor samples were incubated
with a fixable fluorescent viability stain (Life Technologies) for 20 mins (diluted
1:1000 in PBS) prior to incubation with conjugated primary antibodies for 30 mins
at 4 °C. Antibodies were diluted in PBS with 0.5% bovine serum albumin (BSA).
Stained samples were sorted, using the MoFlo XDP or BD Influx cytometer system.
T helper cell culture. Splenic naïve T helper cells from Cyp11a1-mCherry reporter
mice were purified with the CD4+CD62L+T Cell Isolation Kit II (Miltenyi Biotec)
and polarized in vitro toward differentiated Th1, Th2, Th9, Th17, iTreg, and Tfh
subtype following Pramanik et al.65. Naïve cells were seeded into anti-CD3e (2 μg/
ml, clone 145-2C11, eBioscience) and anti-CD28 (5 μg/ml, clone 37.51,
eBioscience) coated plates. The medium contained the following cytokines and/or
antibodies as described below. To culture Th1 subtype: recombinant murine IL2
(10 ng/ml, R&D Systems), recombinant murine IL12 (10 ng/ml, R&D Systems),
and neutralizing anti-IL4 (10 μg/ml, clone 11B11, eBioscience). Th2 subtype:
Recombinant murine IL2 (10 ng/ml, R&D Systems), recombinant murine IL-4
(10 ng/ml, R&D Systems), and neutralizing anti-IFNg (10 μg/ml, clone XMG1.2,
eBioscience). Th9 subtype: 20 ng/ml recombinant mouse IL4, 2 ng/ml recombinant
human TGFb, and 10μg/ml neutralizing anti-IFNγ. Th17 subtype: 30 ng/ml
recombinant mouse IL6, 5 ng/ml recombinant human TGFb, and 50 ng/ml
recombinant mouse IL23. Tfh subtype: 50 ng/ml recombinant mouse IL21, 10 μg/
ml neutralizing anti-IL4 and anti-IFNγ. iTreg subtype: 5 ng/ml recombinant mouse
IL2, 5 ng/ml recombinant human TGFb. The cells were removed from the acti-
vation plate on day 4 (after 72 h). Th2 cells were cultured for another 2 days in the
absence of CD3e and CD28 stimulation. Then, cells were restimulated by seeding
on coated plate for 6 h. For flow cytometric detection cells were treated with
monensin (2 μM, eBioscience) for the last 3 h.
In vitro Tc1 and Tc2 differentiation. Splenic naïve CD8+ T cells were purified by
using Naive CD8a+ T Cell Isolation Kit, mouse (Miltenyi Biotec) following
the manufacturers protocol, and polarized in vitro toward differentiated Tc1 and
Tc2. In brief, naive cells were seeded into anti-CD3e (2 μg/ml, clone 145-2C11,
eBioscience) and anti-CD28 (5 μg/ml, clone 37.51, eBioscience) coated plates. The
medium contained the following cytokines and/or antibodies:
Tc1 subtype: recombinant murine IL2 (10 ng/ml, R&D Systems), recombinant
murine IL12 (10 ng/ml, R&D Systems) and neutralizing anti-IL4 (10 μg/ml, clone
11B11, eBioscience). Tc2 subtype: Recombinant murine IL2 (10 ng/ml, R&D
Systems), recombinant murine IL-4 (10 ng/ml, R&D Systems) and neutralizing
anti-IFNg (10 μg/ml, clone XMG1.2, eBioscience).
Single-cell RNA sequencing. Single cells were isolated from processed B16-F10
subcutaneous tumors using a fluorescence-activated cell sorter. Once processed,
tumor tissues were incubated with a fixable fluorescent viability stain (Live-Dead
Violet, Life Technologies) for 15 mins (diluted 1:1000 in PBS) prior to incubation
with conjugated primary antibodies for 30 mins at 4 °C in the dark. Antibodies
were diluted in flow cytometry staining buffer (eBioscience/Thermo Fisher Sci-
entific). After staining, samples were sorted using the BD influx flow cytometer.
Single-cells were harvested in 2 μl of Lysis Buffer (1:20 solution with RNase
Inhibitor (Clontech, cat. no. 2313 A) in 0.2% v/v Triton X-100 (Sigma-Aldrich, cat.
no. T9284)) in 96-well plates. After sorting the plates were spun down quickly and
kept frozen at −80 °C. Then we performed reverse transcription (RT) and cDNA
pre-amplification following SmartSeq2 protocol to obtain mRNA libraries from
single-cells. Oligo-dT primer, dNTPs (ThermoFisher, cat. no. 10319879) were then
added to the samples. RT-PCR were performed using 50U of SMARTScribe™
Reverse Transcriptase (Clontech, cat. no. 639538). cDNA libraries were prepared
using the Nextera XT DNA Sample Preparation Kit (Illumina, cat. no. FC-131-
1096), following the protocol supplied by Fluidigm (PN 100−5950 B1). Single-cell
libraries were pooled, purified using AMPure XP beads (Beckman Coulter) and
sequenced on an Illumina HiSeq 2500 aiming for an average depth of 1 million
reads/cell (paired-end 100-bp reads).
Single-cell RNA sequencing analysis. The sequencing data was mapped using
STAR 2.5.1b and quantified using htseq 0.9.0. The data was subsequently processed
in Scanpy 1.3.6 with the standard Seurat-inspired workflow. Cells with above 20%
mitochondrial reads were removed, and the data was transformed to log(CPM/100
+ 1) form. Highly variable genes were identified via normalized dispersion, with
the top 10% of genes reported as variable. The data was filtered to highly variable
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genes, scaled and used for PCA. The top 20 principal components were used to
infer a neighbor graph, which served as the basis of UMAP dimensionality
reduction and Leiden clustering with a 0.4 resolution value. Per-cluster markers
were identified using default Scanpy settings, using log(CPM/100+ 1) data on
input. Genes correlated with Cyp11a1 were identified with the Pearson Correlation
Coefficient. Potential Cyp11a1 regulators were detected via pySCENIC, replicating
the demonstration notebook.
ATAC-seq. Naïve T cells isolation and in vitro T helper cell differentiation were
carried out as described above. After 72 h of continuous activation/differentiation,
Th1, Th2, and Th17 cells were harvested. The ATAC-seq experiments were per-
formed following the published protocol with some modification66. Briefly, 50,000
cells were washed with ice-cold 1X Dulbecco's PBS (twice), and resuspended in a
sucrose swelling buffer (0.32 M sucrose, 10 mM Tris.Cl, pH 7.5, 3 mM CaCl2, 2
mM MgCl2, 10% glycerol). The cell suspension was incubated for 10 m on ice. In
next, a final concentration of 0.5% NP-40 was added, and the cells suspension was
vortexed for 10 s and incubated for 10 m on ice. Nuclei were pelleted at 500 × g at
4 °C for 10 m. Then, the nuclei pellets were washed once with 1X TD buffer (from
Nextera DNA Library Preparation Kit, Illumina, #FC-121-1030), and resuspended
in 50 ul tagmentation mixture that contains 25 ul 2X TD buffer (Nextera DNA
Library Preparation Kit, Illumina #FC-121-1030), 22.5 ul H2O, 2.5 ul TDE1
(Nextera DNA Library Preparation Kit, Illumina #FC-121-1030). The tagmentation
reaction was performed on an Eppendorf ThermoMixer C at 37 °C, 800 rpm, for
30 m. The reaction was stopped by adding 250 μl (5 vol) Buffer PB (QIAGEN
MinElute PCR Purification Kit). The tagmented DNA was purified by QIAGEN
PCR Purification Kit according to manufacturer’s instructions and eluted in 12.5 μl
Buffer EB from the kit, which yielded ~10 μl purified DNA. The library amplifi-
cation was performed in a 25-μl reaction that includes 10 μl purified DNA (from
above), 2.5 μl PCR Primer Cocktail (Nextera DNA Library Preparation Kit, Illu-
mina #FC-121-1030), 2.5 μl N5xx (Nextera index kit, Illumina #FC-121-1012),
2.5 μl N7xx (Nextera index kit, Illumina #FC-121-1012), and 7.5 μl NPM PCR
master mix (Nextera DNA Library Preparation Kit, Illumina #FC-121-1030). PCR
reaction condition was: 72 °C 5m, 98 °C 2 m, [98 °C 10 s, 63 °C 30 s, 72 °C 60 s] ×
12, 10 °C hold. Amplified libraries were purified by double Agencourt AMPureXP
beads purifications (Beckman Coulter, #A63882). 0.4X beads:DNA ratio for the
first time, flow through was kept (removing large fragments); 1.4X beads: DNA
ratio for the second time, beads were kept. Libraries were eluted from the beads in
20 μl Buffer EB (from QIAGEN PCR Purification Kit). In all, 1 μl library was run
on an Agilent Bioanalyzer to check size distribution and quality of the libraries.
Sequencing was done by an Illumina Hiseq 2500 (75 bp PE).
ATAC-seq data processing. ATAC-seq reads were aligned using Bowtie 267 with
the parameter –X 2000 and the mouse genome mm10. This was followed by peak
calling on each replicate individually using MACS268 with the function callpeak
and the parameters -B -SPMR -shift -100 -extsize 200. The peaks obtained were
kept if they overlapped a peak from the other replicate of the same T helper cell
types. The resulting bedGraph files generated by MACS2 were converted to bigWig
format for the visualization on UCSC genome browser69.
ChIP-seq data processing. GATA3 ChIP-seq data sets from different Tn subtypes
were downloaded from the NCBI GEO database (GSE20898)70. The SRA files were
converted to fastq files using the SRA toolkits (http://ncbi.github.io/sra-tools/).
Reads were aligned to the mm10 genome using Bowtie 267 with default parameters.
Peak calling was performed by using MACS268 with the function callpeak and the
parameters -B -SPMR -nomodel -extsize 200. The resulting bedGraph files gen-
erated by MACS2 were converted to bigWig format for the visualization on UCSC
genome browser69.
B16-F10 and T cell co-culture assay. Negatively purified splenic naïve CD4+
T cells from Cyp11a1-mCherry mice were cultured in presence of B16-F10 cell with
or without TCR activation and analyzed by flow cytometry to detect Cyp11a1-
mCherry expression. Naïve T cell purification and activation condition is described
in the T helper cell culture section above. Briefly, naïve splenic cells were activated
in anti-CD3e and anti-CD28 coated plate in presence of IL2 but absence anti-IL4
neutralizing antibody.
Quantitative PCR. Tumor-infiltrating macrophages (Lin−CD11b+) and CD8+
T cells were purified by cell sorting. We used the Cells-to-CT kit (Invitrogen/
Thermofisher Scientific) and followed SYBR Green format according to manu-
facturer’s instructions. In all, 2 μl of cDNA was used in 12 μl qPCR reactions with
appropriate primers and SYBR Green PCR Master Mix (Applied Biosystems). Data
were analyzed by ddCT method. Experiments were performed three times and data
represent mean values ± standard deviation. The primer list is provided below:
Arg1: F- ATGGAAGAGACCTTCAGCTAC
R- GCTGTCTTCCCAAGAGTTGGG
Tgfβ1: F- TGACGTCACTGGAGTTGTACGG
R- GGTTCATGTCATGGATGGTGC
Ifnγ: F- ACAATGAACGCTACACACTGC
R- CTTCCACATCTATGCCACTTGAG;
Tnfα: F- CATCTTCTCAAAATTCGAGTGACAA
R- TGGGAGTAGACAAGGTACAACCC
Gapdh: F- ACCACAGTCCATGCCATCAC
R- GCCTGCTTCACCACCTTC
Rplp0: F: CACTGGTCTAGGACCCGAGAA
R: GGTGCCTCTGGAGATTTTCG
Flow cytometry. We followed eBioscience surface staining, intracellular cytoto-
plasmic protein staining (for cytokines) protocols. Briefly, single-cell suspensions
were stained with Live/Dead Fixable Dead cell stain kit (Molecular Probes/ Thermo
Fisher) and blocked by purified rat anti-mouse CD16/CD32 purchased from BD
Bioscience and eBioscience. Surface staining was performed in flow cytometry
staining buffer (eBioscience) or in PBS containing 3% FCS at 4 °C. For intracellular
cytokine staining cells were fixed by eBioscience IC Fixation buffer and permea-
bilized by eBioscience permeabilization buffer. Cells were stained in 1x permea-
bilization buffer with fluorescent dye-conjugated antibodies. After staining cells
were washed with flow cytometry staining buffer (eBioscience) or 3% PBS-FCS, and
were analyzed by flow cytometer Fortessa (BD Biosciences) using FACSDiva. The
data were analyzed by FlowJo v10.2 software. Antibodies used in flow cytometry
were: CD4 (RM4-5 or GK1.5), eBioscience, BD Bioscience and Biolegend. 1:400;
CD8a (53-6.7), eBioscience 1:400; CD3e (145 2c11), eBioscience 1:400; TCRb
(H57-597, BB790) BD Bioscience 1:400; CD45 (30F11), BD Bioscience 1:1000;
CD44 (IM7), eBioscience 1:400; CD25 (PC61), BD Bioscience 1:400; B220 (Ra3-
6b2), eBioscience 1:400; Ly6G (1A8), eBioscience 1:400; Ly6G/Ly6C/Gr-1 (RB6-
8C5), eBioscience 1:400; Ly6C (HK1.4), eBioscience 1:400; SiglecF (E50-2440) BD
Bioscience 1:1000; CD11b (M1/70), eBioscience 1:400; CD11c (N418), eBioscience
1:400; CD19 (1D3), eBioscience 1:400; NK1.1 (Pk136), Biolegend 1:400; Ter119
(TER119), eBioscience 1:400; PD-1 (J43), eBioscience 1:400; TIGIT (1G9), BD
Bioscience 1:400; CD107a/LAMP1 (1D4B), eBioscience 0.5 μg/test(100ul); IFNg
(XMG1.2) PerCP-Cy5.5 eBioscience 1:1500 Cat no. 45-7311-82; IL4 (11B11) APC
eBioscience 1:200 Cat no 17-7041-82; IL13 (eBio13a) AF488 eBioscience, 1:400,
Cat. no. 53-7133-82; IL17 (eBio64DEC17), APC, 1:200, Cat. no. 17-7179-42;
CD117(2B8) BV711, BD Bioscience, cat no. 563160.
Western blot antibodies. Anti-CYP11A1 (Santa Cruz Biotechnology, C-16) and
anti-TBP (Abcam) were used.
Quantitative ELISA. CD45+ leukocytes were purified from B16-F10 tumor masses
and lungs, of mice that had been tail vein administered B16-F0 cells, and seeded at
equal density in IMDM medium supplemented with 10% charcoal stripped
FBS (Life Technologies, Invitrogen) for 24 h. Pregnenolone concentrations of the
culture supernatants were quantified using pregnenolone ELISA kit (Abnova) and
corticosteroids ELISA (Thermofisher) kit following the manufacturers’ instruction.
Absorbance was measured at 450 nm, and data were analyzed in GraphPad Prism 6.
T cell proliferation assay. Negatively purified splenic naïve CD4+ T cells were
purified from Cyp11a1 cKO, Cd4-Cre and Cyp11a1fl/fl mice, stained with CellTrace
Violet following the CellTrace Violet Cell Proliferation Kit (Invitrogen) protocol,
activated in vitro, and the cell proliferation profile was captured by flow cytometry
based dye decay assay on BD Fortessa65. Data were analyzed in FlowJo v9.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
scRNAseq data is deposited to ArrayExpress with accession number E-MTAB-8509
[https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-8509/]. The ATACseq data
(exclusively generated for this study) is in ENA and deposited within a large study name
with many other data sets. The accession number in ENA is PRJEB14081 [https://www.
ebi.ac.uk/ena/data/search?query=PRJEB14081]. The sample info and run numbers
referring to the ATAC-seq data we used in the manuscript can be found in the
spreadsheet provided as Supplementary Data 1. GATA3 ChIP-seq data sets from
different Tn subtypes were downloaded from the NCBI GEO database (GSE20898)
[https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20898]. The raw data source
of Fig. 3j was GSE1923471 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE19234] and Fig. 2l was EGAD0000100032572 [https://www.ebi.ac.uk/ega/
datasets/EGAD00001000325]. Access to EGAD00001000325 dataset is available upon
request to the Data Access Committee at datasharing@sanger.ac.uk. In Supplementary
Fig. 2g we searched “Expression Atlas (EMBL-EBI)” with search query gene name
“Cyp11a1”, species “Homo sapiens”, “cancer” as disease condition, baseline expression,
arranged by expression rank, downloaded data, rebuilt the figure, excluded ovarian
cancer to avoid confusion. Link for the search is provided below: https://www.ebi.ac.uk/
gxa/search?geneQuery=%5B%7B%22value%22%3A%22Cyp11a1%22%7D%
5D&species=homo%20sapiens&conditionQuery=%5B%7B%22value%22%3A%
22cancer%22%7D%5D&bs=%7B%22homo%20sapiens%22%3A%5B%22DISEASE%22%
5D%7D&ds=%7B%22kingdom%22%3A%5B%22animals%22%5D%7D#baseline.
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Supporting data for the Supplementary Fig. 4j–i can be found in the Supplementary
Data 2. All remaining relevant data are available in the article, supplementary
information, or from the corresponding author upon reasonable request.
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